Romidepsin
- Generic Name
- Romidepsin
- Brand Names
- Istodax
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36N4O6S2
- CAS Number
- 128517-07-7
- Unique Ingredient Identifier
- CX3T89XQBK
Overview
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Background
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Indication
用于在已接受至少1次既往全身治疗的患者中皮肤T-细胞淋巴瘤的治疗(CTCL)。
Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
Clinical Trials
FDA Approved Products
Romidepsin
Manufacturer:Teva Parenteral Medicines, Inc.
Route:INTRAVENOUS
Strength:5 mg in 1 mL
Approved: 2021/12/31
NDC:0703-4004
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath